Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
KRAS G12C mutation Solid Tumors | Phase 1 | CN | - | 27 Sep 2021 |
Advanced Malignant Solid Neoplasm | Preclinical | CN | 27 Oct 2022 | |
Colorectal Cancer | Preclinical | CN | 27 Oct 2022 | |
KRAS mutation-related tumors | Preclinical | CN | 27 Oct 2022 | |
Non-Small Cell Lung Cancer | Preclinical | CN | 27 Oct 2022 |